FibroBiologics director granted 30,803 stock options

FibroBiologics, Inc. director Matthew Link received a grant of stock options covering 30,803 shares of common stock.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

FibroBiologics, Inc. director Matthew Link received a grant of stock options covering 30,803 shares of common stock. The options have an exercise price of $0.7503 per share and expire on June 22, 2036. Following this grant, he holds options for 30,803 shares directly. The options vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting.

Insider Trade Summary

Grant/Award: 30,803 shares

Grant/Award 1 txn

Insider Link Matthew

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	30,803	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 30,803 contracts (Direct)

Footnotes (1)

F1. The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting.

Key Figures

Option grant size: 30,803 options Exercise price: $0.7503 per share Expiration date: June 22, 2036 +2 more

5 metrics

Option grant size 30,803 options Stock Option (Right to Buy) granted to director Matthew Link

Exercise price $0.7503 per share Exercise price of stock options on FibroBiologics common stock

Expiration date June 22, 2036 Option expiration date for the granted stock options

Underlying shares 30,803 shares Common stock underlying the granted options

Total options after grant 30,803 options Total derivative securities held following this transaction

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "0.7503""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The options will vest in full upon the earlier of the first anniversary of the date of grant or the date of the next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did FibroBiologics (FBLG) report for Matthew Link?

FibroBiologics reported that director Matthew Link received a grant of stock options for 30,803 shares of common stock. These options were awarded as compensation, not purchased in the open market, and give him the right to buy shares at a fixed exercise price.

How many FibroBiologics (FBLG) shares are covered by Matthew Link’s new options?

The new stock option grant to director Matthew Link covers 30,803 shares of FibroBiologics common stock. This entire amount is reflected as his total option holdings after the transaction, indicating this filing shows a newly awarded equity position rather than a trade.

What is the exercise price and expiration date of Matthew Link’s FibroBiologics options?

Matthew Link’s stock options have an exercise price of $0.7503 per share and expire on June 22, 2036. This means he can buy up to 30,803 shares at that fixed price any time before the expiration, subject to vesting conditions.

When do Matthew Link’s FibroBiologics (FBLG) stock options vest?

The options vest in full upon the earlier of the first anniversary of the grant date or the date of the next annual shareholder meeting. This time-based vesting schedule means he must remain in his role until one of those milestones for the options to fully vest.

Did Matthew Link buy or sell any FibroBiologics (FBLG) shares in this Form 4?

This Form 4 reports a grant of stock options to Matthew Link, not a market purchase or sale of shares. The transaction is coded as a grant or award acquisition, reflecting routine equity compensation rather than open-market trading activity in FibroBiologics stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 08:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Link Matthew

(Last)

(First)

(Middle)

C/O FIBROBIOLOGICS, INC.

9350 KIRBY DRIVE., SUITE 300

(Street)

HOUSTON,

TEXAS

77054

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FibroBiologics, Inc. [ FBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.7503	06/23/2026		A		30,803		⁽¹⁾	06/22/2036	Common Stock	30,803	$0	30,803	D

Explanation of Responses:

1. The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting.

	/s/ Ruben A. Garcia, by Power of Attorney	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR